SG11202004079PA - Treatment of post-traumatic syndrome disorder - Google Patents

Treatment of post-traumatic syndrome disorder

Info

Publication number
SG11202004079PA
SG11202004079PA SG11202004079PA SG11202004079PA SG11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA SG 11202004079P A SG11202004079P A SG 11202004079PA
Authority
SG
Singapore
Prior art keywords
post
treatment
traumatic syndrome
syndrome disorder
disorder
Prior art date
Application number
SG11202004079PA
Inventor
Alessandra Mascarello
Cristiano Ruch Werneck Guimarães
Hatylas Felype Zaneti De Azevedo
Marcos Antonio Ferreira Junior
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of SG11202004079PA publication Critical patent/SG11202004079PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004079PA 2017-12-14 2018-12-14 Treatment of post-traumatic syndrome disorder SG11202004079PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598757P 2017-12-14 2017-12-14
PCT/BR2018/050461 WO2019113668A2 (en) 2017-12-14 2018-12-14 Treatment of post-traumatic syndrome disorder

Publications (1)

Publication Number Publication Date
SG11202004079PA true SG11202004079PA (en) 2020-05-28

Family

ID=66818829

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004079PA SG11202004079PA (en) 2017-12-14 2018-12-14 Treatment of post-traumatic syndrome disorder

Country Status (12)

Country Link
US (1) US20210221774A1 (en)
EP (1) EP3723759B1 (en)
JP (1) JP2021506796A (en)
KR (1) KR20200099153A (en)
CN (1) CN111601600A (en)
AU (1) AU2018384087A1 (en)
BR (1) BR112020011586A2 (en)
CA (1) CA3084623C (en)
ES (1) ES2969657T3 (en)
MX (1) MX2020005459A (en)
SG (1) SG11202004079PA (en)
WO (1) WO2019113668A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1003506B1 (en) * 2010-09-24 2019-12-03 Ache Int Bvi Ltd alkyl-piperazine-phenyl-4 (3h) quinazolinone compound and use of the alkyl-piperazine-phenyl-4 (3h) quinazolinone compound associated with 5-ht1a and 5-ht2a serotonergic receptors
EP3130339B1 (en) * 2015-08-14 2020-05-06 Aché Laboratórios Farmacêuticos S.A. A compound for use in the treatment of comorbid anxiety disorder and depression disorder

Also Published As

Publication number Publication date
WO2019113668A2 (en) 2019-06-20
US20210221774A1 (en) 2021-07-22
MX2020005459A (en) 2020-09-07
ES2969657T3 (en) 2024-05-21
EP3723759A4 (en) 2021-09-08
EP3723759C0 (en) 2024-01-10
KR20200099153A (en) 2020-08-21
CA3084623A1 (en) 2019-06-20
EP3723759A2 (en) 2020-10-21
CA3084623C (en) 2023-05-16
BR112020011586A2 (en) 2020-12-08
WO2019113668A3 (en) 2019-12-19
JP2021506796A (en) 2021-02-22
AU2018384087A1 (en) 2020-05-21
EP3723759B1 (en) 2024-01-10
CN111601600A (en) 2020-08-28

Similar Documents

Publication Publication Date Title
IL283258A (en) Treatment of hypoparathyroidism
HK1254287A1 (en) Treatment of fibrosis
IL274865A (en) Methods of treatment with asparaginase
IL262852A (en) Treatment of complement-mediated disorders
ZA201908616B (en) Formulations for treatment of post-traumatic stress disorder
IL262419A (en) Cannabis-enriched enzymatically treated therapeutic composition
IL259856A (en) Composition for treatment of crigler-najjar syndrome
HK1231386A1 (en) Treatment of immune disorders
HK1249865B (en) Treatment of pain
IL265259A (en) Treatment of multiple sclerosis with chs-131
GB201413530D0 (en) Treatment and prevention of malaria
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11202004079PA (en) Treatment of post-traumatic syndrome disorder
PL3582764T3 (en) Treatment of alcohol use disorder
GB201615298D0 (en) Treatment and prevention of Malaria
SG10201913141UA (en) Treatment of alphavirus-induced inflammation
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201518002D0 (en) Ketamine for the treatment of somatoform pain disorder
GB201516418D0 (en) Treatment of acute inflammatory disorders
GB201516140D0 (en) Treatment of acute inflammatory disorders